Key Takeaways
- • Armistice Capital recorded its third consecutive month of losses in 2025, with a devastating 19% decline in March—the worst monthly performance for its flagship fund since inception over a decade ago.
- • The $2 billion equity long-short hedge fund imposed full-year lockup terms effective January 1, 2025, preventing investors from withdrawing capital despite mounting losses, amplifying investor dissatisfaction.
- • Collateral damage from multi-manager hedge fund redemptions in March exacerbated losses, as broader market retreats from equities added selling pressure to Armistice's concentrated biotech and healthcare portfolio.
- • Continued losses extended through April, signaling persistent performance challenges beyond the March market dislocation and raising questions about the fund's positioning and risk management.
Summary
Armistice Capital, a $2 billion equity long-short hedge fund specializing in biotech and healthcare investments, has faced a severe performance crisis in 2025, suffering three consecutive months of losses while operating under restrictive withdrawal terms that prevent investors from exiting their positions.
The fund's flagship vehicle posted a 19% loss in March—its largest monthly decline since launching over a decade ago. This marked the beginning of a losing streak that extended through April, according to multiple sources. The March downturn coincided with a broader market contraction when multi-manager hedge funds retreated from equities and added significant selling pressure across the market, creating collateral damage for concentrated equity positions like those held by Armistice.
The timing of these losses is particularly problematic for investors because Armistice implemented new lockup terms effective January 1, 2025, that restrict capital redemptions for the entire calendar year. This decision to lock up investor capital for the full year, which the Wall Street Journal reported previously, left shareholders unable to exit positions despite the fund's deteriorating performance. The combination of mounting losses and forced capital retention has generated substantial investor unhappiness.
Armistice Capital's portfolio focus on healthcare and consumer sectors, combined with its long/short, value-oriented and event-driven strategy, appeared vulnerable to the specific market dynamics that emerged in early 2025. The concentrated nature of the fund's biotech holdings left it particularly exposed to the selling pressure that accompanied broader hedge fund repositioning in March. The persistence of losses into April suggests the initial March downturn was not merely a temporary market shock but reflects potential structural challenges in the fund's positioning or the performance of its core holdings.
The fund's flagship vehicle posted a 19% loss in March—its largest monthly decline since launching over a decade ago. This marked the beginning of a losing streak that extended through April, according to multiple sources. The March downturn coincided with a broader market contraction when multi-manager hedge funds retreated from equities and added significant selling pressure across the market, creating collateral damage for concentrated equity positions like those held by Armistice.
The timing of these losses is particularly problematic for investors because Armistice implemented new lockup terms effective January 1, 2025, that restrict capital redemptions for the entire calendar year. This decision to lock up investor capital for the full year, which the Wall Street Journal reported previously, left shareholders unable to exit positions despite the fund's deteriorating performance. The combination of mounting losses and forced capital retention has generated substantial investor unhappiness.
Armistice Capital's portfolio focus on healthcare and consumer sectors, combined with its long/short, value-oriented and event-driven strategy, appeared vulnerable to the specific market dynamics that emerged in early 2025. The concentrated nature of the fund's biotech holdings left it particularly exposed to the selling pressure that accompanied broader hedge fund repositioning in March. The persistence of losses into April suggests the initial March downturn was not merely a temporary market shock but reflects potential structural challenges in the fund's positioning or the performance of its core holdings.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.